Vamil Divan
Stock Analyst at Guggenheim
(4.66)
# 215
Out of 4,667 analysts
210
Total ratings
66.92%
Success rate
16.6%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $156 → $162 | $153.11 | +5.81% | 11 | Nov 6, 2024 | |
| ABBV AbbVie | Maintains: Buy | $212 → $221 | $167.76 | +31.74% | 22 | Nov 6, 2024 | |
| VERA Vera Therapeutics | Maintains: Buy | $56 → $64 | $45.75 | +39.89% | 4 | Oct 28, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $41 | $17.86 | +129.56% | 7 | Oct 9, 2024 | |
| ABSI Absci | Initiates: Buy | $10 | $2.68 | +273.13% | 1 | Oct 2, 2024 | |
| KROS Keros Therapeutics | Initiates: Buy | $96 | $54.14 | +77.32% | 1 | Sep 23, 2024 | |
| PROK ProKidney | Initiates: Buy | $6 | $1.65 | +263.64% | 1 | Sep 10, 2024 | |
| INSM Insmed | Maintains: Buy | $70 → $95 | $72.67 | +30.73% | 4 | Jul 9, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Neutral | n/a | $2.66 | - | 2 | Jun 18, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $3.80 | +110.53% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $77 | $55.10 | +39.75% | 8 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $24.94 | +44.35% | 18 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $4.91 | +307.33% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $2.85 | +812.28% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.18 | +662.71% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.70 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $16.27 | +16.78% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $123.29 | -20.51% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $27.91 | +21.82% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.26 | +342.48% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $94.60 | -48.20% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $753.41 | -52.75% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $3.06 | +96.08% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $46.83 | +228.85% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $12.63 | +18.76% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.64 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $17.03 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $81 | $97.44 | -16.87% | 12 | Oct 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $8.24 | +82.04% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $57.88 | +5.39% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.41 | +4,173.86% | 3 | Jan 17, 2018 |
Johnson & Johnson
Nov 6, 2024
Maintains: Neutral
Price Target: $156 → $162
Current: $153.11
Upside: +5.81%
AbbVie
Nov 6, 2024
Maintains: Buy
Price Target: $212 → $221
Current: $167.76
Upside: +31.74%
Vera Therapeutics
Oct 28, 2024
Maintains: Buy
Price Target: $56 → $64
Current: $45.75
Upside: +39.89%
Travere Therapeutics
Oct 9, 2024
Maintains: Buy
Price Target: $23 → $41
Current: $17.86
Upside: +129.56%
Absci
Oct 2, 2024
Initiates: Buy
Price Target: $10
Current: $2.68
Upside: +273.13%
Keros Therapeutics
Sep 23, 2024
Initiates: Buy
Price Target: $96
Current: $54.14
Upside: +77.32%
ProKidney
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $1.65
Upside: +263.64%
Insmed
Jul 9, 2024
Maintains: Buy
Price Target: $70 → $95
Current: $72.67
Upside: +30.73%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.66
Upside: -
Revance Therapeutics
May 10, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $3.80
Upside: +110.53%
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $55.10
Upside: +39.75%
Feb 23, 2024
Initiates: Buy
Price Target: $36
Current: $24.94
Upside: +44.35%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $4.91
Upside: +307.33%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $2.85
Upside: +812.28%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.18
Upside: +662.71%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.70
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $16.27
Upside: +16.78%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $123.29
Upside: -20.51%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $27.91
Upside: +21.82%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.26
Upside: +342.48%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $94.60
Upside: -48.20%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $753.41
Upside: -52.75%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $3.06
Upside: +96.08%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $46.83
Upside: +228.85%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $12.63
Upside: +18.76%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $25.64
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $17.03
Upside: -
Oct 11, 2018
Maintains: Outperform
Price Target: $71 → $81
Current: $97.44
Upside: -16.87%
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $8.24
Upside: +82.04%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $57.88
Upside: +5.39%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.41
Upside: +4,173.86%